Drug developers integrate AI capabilities as a potentially transformative strategy to combat patent cliff losses.

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...

Scientists in Seoul have uncovered 15 gut bacterial species linked to coronary artery disease, showing that microbes can influence heart health far beyond digestion. Their findings reveal how shifts ...

On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan, which would lower drug prices by codifying the savings from his Most-Favored-Nation pricing initiative, ...

Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA ...

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

The Supraventricular Tachycardia market benefits from aging populations, technological advances like catheter ablation, rising cardiovascular awareness, and wearable diagnostics. Growth is supported ...

Jan 25 (Reuters) - Merck (MRK.N), opens new tab is no longer in discussions to buy cancer drug developer Revolution Medicines (RVMD.O), opens new tab, the Wall Street Journal reported on Sunday. The ...

Merck MRK1.78%increase; green up pointing triangle is no longer in discussions to buy biotech Revolution Medicines RVMD-1.27%decrease; red down pointing triangle, according to people familiar with the ...

With $30 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), Merck & Co. is bringing together several global vaccine makers to develop an updated Ebola vaccine to ...

About every 34 seconds, someone, somewhere in the United States dies from heart disease — which remains the leading cause of death for both men and women, according to the American Heart Association.

A TV commercial for bempedoic acid/ezetimibe (Nexlizet) was deemed "false or misleading" by the FDA due to claims the drug is the only nonstatin to lower bad cholesterol and reduce the risk of heart ...